Which STDs Can Be Detected With a Urine Test?

Urine testing reliably detects chlamydia, gonorrhea, and trichomoniasis, and it can also pick up Mycoplasma genitalium with newer assays. These four infections account for the bulk of routine urine-based STD screening. Beyond them, the picture gets more limited: most viral STDs and syphilis still depend on blood draws or swabs rather than a urine cup. The reason has less to do with technology than with biology, specifically where each pathogen lives in the body and how much of it ends up in urine.

Chlamydia and Gonorrhea Are the Standard Urine Tests

When a clinic offers a “urine STD test,” it almost always means a test for Chlamydia trachomatis and Neisseria gonorrhoeae. These two bacterial infections are the most commonly reported STDs in many countries, and urine-based screening has been routine for years. The tests used are nucleic acid amplification tests, which detect tiny amounts of bacterial DNA or RNA in the sample. They replaced older culture-based methods that caught roughly half of actual infections; modern amplification tests nearly doubled the detection rate compared to culture.¹

For men, urine performs exceptionally well. A systematic review for the US Preventive Services Task Force found sensitivities ranging from 93% to 100% for gonorrhea detection in male urine, with specificity above 99%.² That tracks with the biology: in men, these bacteria colonize the urethra, and urine washes right over the infection site on its way out.

For women, urine still works but is measurably less sensitive than vaginal swabs. A meta-analysis found pooled sensitivity for chlamydia was about 87% in urine versus 94% for vaginal swabs, and for gonorrhea about 91% versus 97%.³ The gap exists because the cervix, where these bacteria often reside in women, is further from the urinary stream. A vaginal swab collects directly from the infection site. That said, the difference is small enough that urine remains a widely accepted screening option, and many people prefer it to a swab.

Trichomoniasis

Trichomonas vaginalis, the parasite responsible for trichomoniasis, is also detectable in urine. This is sometimes overlooked because trichomoniasis testing has historically relied on vaginal wet-mount microscopy, a method with mediocre sensitivity. Newer molecular assays have changed the game. One large multicenter evaluation of the cobas TV/MG test found 100% sensitivity for trichomoniasis in male urine samples, with specificity around 98%.⁴ For women, vaginal swabs still outperform urine (about 99% versus 95% sensitivity in meta-analysis data), but urine catches most infections and is far more convenient than an in-clinic exam.³

Trichomoniasis in men is sometimes thought of as uncommon, but that impression partly reflects the fact that until recently, detection methods were poor. Studies comparing culture and molecular testing in male partners of infected women showed that urine-based molecular methods picked up infections that swabs and culture missed.⁵ Point-of-care rapid tests for trichomoniasis in male urine have also shown strong sensitivity, around 97%.⁶

Mycoplasma Genitalium

Mycoplasma genitalium is a relative newcomer to routine STD screening, but urine-based tests for it are now commercially available. This bacterium causes urethritis in men and has been linked to cervicitis and pelvic inflammatory disease in women. The cobas TV/MG assay detected M. genitalium in male urine with 100% sensitivity and in female urine with about 86% sensitivity, though vaginal swabs performed better in women at around 97%.⁷ One practical wrinkle: the type of molecular test used matters more than usual with M. genitalium because it is a fastidious organism present in lower quantities. One study found that transcription-mediated amplification detected M. genitalium in urine at significantly higher rates than real-time PCR, and the advantage widened as samples sat longer before processing.⁸

Not every clinic routinely tests for M. genitalium, and guidelines on when to screen are still evolving. If you have persistent urethritis symptoms that do not resolve after standard chlamydia and gonorrhea treatment, asking specifically about M. genitalium testing is reasonable.

What Urine Tests Cannot Reliably Detect

Several major STDs are not part of standard urine screening, and for good reasons.

Syphilis is diagnosed through blood-based serology. There have been isolated case reports of syphilis DNA showing up in urine via real-time PCR, but these are incidental findings, not a validated screening method. One report described detecting Treponema pallidum DNA in the urine of three patients, noting that this “expand[s] the spectrum of noninvasive diagnostic methods” but that “serological testing remains the standard.”⁹ Syphilis is a systemic infection that does not primarily involve the urinary tract, so urine just does not collect enough pathogen material for reliable testing.

HIV is another infection where urine testing exists in a limited sense but is not the standard approach. Urine-based HIV antibody rapid test kits have been evaluated, primarily in China, but they come with notable drawbacks. One real-world evaluation found a false-negative rate of over 6% in certain populations, with failures concentrated among people with recent infections and those on antiretroviral therapy.¹⁰ Blood-based tests and oral fluid rapid tests remain more accurate and more widely available.

Hepatitis B is sometimes listed among STDs, and while HBV DNA fragments can appear in urine, research has concluded that urine from patients with chronic hepatitis B and healthy kidneys does not contain full-length virus and should not be considered infectious.¹¹ Diagnosis relies on blood tests for surface antigens and antibodies.

Herpes simplex virus (HSV) is diagnosed by swabbing an active lesion or by blood tests for antibodies. No validated urine test for herpes exists.

HPV in Urine Is an Emerging Frontier

Human papillomavirus testing from urine is one of the more active areas of research, driven by the appeal of replacing cervical swabs with something that requires no pelvic exam. An umbrella review of existing meta-analyses found that first-void urine detected any HPV type with about 87% sensitivity and 89% specificity, though the numbers dropped for high-risk HPV strains specifically, to about 78% sensitivity.¹² Those numbers are promising but not yet competitive with cervical samples for clinical decision-making about cancer screening.

How the urine is collected makes a real difference for HPV detection. The first stream of urine picks up more viral DNA shed from genital tissue than a midstream sample. Specialized collection devices designed to capture only the first few milliliters of urine have shown higher HPV DNA concentrations than standard cup collection.¹³ Novel technologies, including nanowire-based extraction methods, have demonstrated high concordance between urine and cervical swab results in proof-of-concept studies.¹⁴ None of these are in routine clinical use yet, but HPV urine testing could become a standard option within the next several years, particularly in settings where access to cervical screening is limited.

Why Collection Technique Matters

If you have ever been handed a urine cup for STD testing and told to collect only the first part of the stream, there is a reason for that instruction. The first-void portion of urine contains the highest concentration of bacterial or viral material shed from the urethra and surrounding genital tissue. One study of women with confirmed chlamydia found that midstream urine still detected 96% of cases that first-void urine caught, so the difference is not dramatic.¹⁵ Still, first-void is preferred when the goal is maximum sensitivity.

You may also have been told not to urinate for at least one or two hours before giving a sample. The idea is that waiting allows bacteria to accumulate in the urethra, giving the test more material to work with. In practice, the evidence on this is reassuring for people who cannot hold it. One study in men found no statistically meaningful difference in chlamydia detection rates between those who had urinated less than two hours before collection and those who waited longer.¹⁶ Another study specifically evaluating short voiding intervals of just 20 minutes found that sensitivity remained “reasonably high” and recommended removing the one-hour hold barrier during opportunistic screening.¹⁷ The practical upshot: follow the instructions if you can, but if you recently used the bathroom before an unexpected opportunity to get tested, go ahead and do the test rather than skipping it.

The Extragenital Blind Spot

One limitation of urine testing that often catches people off guard is that it only detects infections in the genital tract. Chlamydia and gonorrhea can also infect the throat and rectum, and those infections are invisible to a urine test. You could have a negative urine result and still carry an active infection at one of these sites. A study across six high-incidence U.S. states found that only about 58% of clinics offering chlamydia and gonorrhea testing also provided extragenital (throat and rectal) testing.¹⁸ If you have had oral or receptive anal sex, a urine test alone does not provide a complete picture.

This is especially relevant for men who have sex with men, who are at higher risk for rectal and pharyngeal infections that would go undetected by urine screening. Current guidelines from the CDC recommend site-specific testing based on sexual behavior rather than relying on urine alone. If your provider only orders a urine test, it is worth asking whether throat or rectal swabs are appropriate for your situation.

Things That Can Interfere With Results

Modern molecular tests on urine are accurate, but they are not immune to interference. Certain substances naturally found in urine can inhibit the amplification process and produce false-negative results. Research has identified several culprits, including crystals in the urine, nitrites (often associated with urinary tract infections), hemoglobin (from blood in the urine), and beta-hCG, the hormone that rises during pregnancy.¹⁹ Most commercial assays now include internal controls that flag when inhibition has occurred, prompting a re-test. But it is worth being aware that a single negative result on urine is not always the final word, particularly if you have symptoms or a known exposure.

Older screening methods occasionally show up in resource-limited settings or military screenings. The leukocyte esterase test, which detects white blood cells in urine as a sign of inflammation, was once used as a cheap proxy for chlamydia and gonorrhea. Its sensitivity was poor, around 46% for chlamydia and 60% for gonorrhea, compared to molecular testing.²⁰ If your only available test is a dipstick-style urinalysis rather than a molecular test, understand that a negative result carries much less weight.

Home Collection and Point-of-Care Testing

The convenience of urine collection has made it the backbone of home STD testing kits. You order a kit, collect a first-void sample, and mail it to a lab for molecular analysis. Research comparing home-based and clinic-based screening has found that home collection can increase testing rates by as much as eleven times, largely because it removes the barriers of scheduling an appointment, sitting in a waiting room, and discussing sexual history face to face.²¹ Most participants in these studies found self-collection easy and often preferred it to clinic visits.

Point-of-care tests, the kind that could produce a result during a single clinic visit or even at home, are available for syphilis but remain limited for the infections most commonly tested by urine. There are point-of-care molecular platforms for chlamydia, gonorrhea, and trichomoniasis, but they vary widely in accuracy, cost, and turnaround time. None of the current rapid platforms can detect antibiotic resistance in gonorrhea, which is becoming an increasingly urgent concern as drug-resistant strains spread.²² For now, the most reliable urine-based results still come from lab-processed molecular tests, whether the sample is collected at home or in a clinic.

Ureaplasma and Other Organisms Sometimes Reported on STD Panels

Some direct-to-consumer and expanded clinic panels test urine for Mycoplasma hominis, Ureaplasma parvum, and Ureaplasma urealyticum. These organisms can be found in the urogenital tract and are technically detectable in urine by molecular methods. The question is whether detecting them actually helps. A position statement from the European STI Guidelines Editorial Board concluded that there is currently no evidence that testing for and treating these organisms does more good than harm. Asymptomatic carriage is extremely common, and for Ureaplasma urealyticum in particular, colonization without disease accounts for an estimated 40 to 80% of detections.²³

This matters because a positive result on one of these organisms can trigger unnecessary anxiety and antibiotic treatment for what is often harmless colonization. If you receive a result showing Ureaplasma or Mycoplasma hominis on a urine panel, the finding alone does not mean you have an STD that requires treatment. Current expert consensus recommends against routine screening for these organisms in people without symptoms. The fact that a test can detect something in urine does not automatically mean it should.